Actively Recruiting

Phase Not Applicable
Age: 18Years - 60Years
All Genders
NCT05924646

CAlgary SAlt for POTS

Led by University of Calgary · Updated on 2026-05-07

50

Participants Needed

1

Research Sites

242 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend \~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. This randomized, placebo-controlled cross-over trial will evaluate a high salt diet, compared to a normal salt diet over a period of 3 months. Participants will complete 3 in lab evaluations including autonomic function testing, tilt table testing, blood volume and urine sodium evaluation, plasma catecholamine measurements and and cytokine measurements.

CONDITIONS

Official Title

CAlgary SAlt for POTS

Who Can Participate

Age: 18Years - 60Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Physician diagnosis of POTS as defined by the CCS Consensus Statement
  • Sustained excessive orthostatic tachycardia of 30 bpm or more within 10 minutes of standing
  • No orthostatic hypotension (no blood pressure drop >20/10 mmHg in 3 minutes of standing)
  • Chronic orthostatic symptoms that improve when lying down
  • Age between 18 and 60 years old
  • Ability to attend the Calgary Autonomic Research Clinic in Calgary
  • Resident of Canada
Not Eligible

You will not qualify if you...

  • Known cause of postural tachycardia such as acute dehydration or thyroid disease
  • Presence of somatization or severe anxiety symptoms
  • Pregnant women (self-reported)
  • Underlying causes of tachycardia including acute hypovolemia, endocrinopathy, anemia, anxiety, medication or recreational drug effects, and prolonged bedrest
  • Any factor judged by the investigator to prevent study completion, including poor compliance in past studies
  • Use of fludrocortisone due to its effects on kidney salt handling
  • Receipt of intravenous saline in the two months before or planned during the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Calgary

Calgary, Alberta, Canada, T2N 4Z6

Actively Recruiting

Loading map...

Research Team

S

Satish R Raj, MD MSCI

CONTACT

T

Tanya Siddiqui, MBBS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here